{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T11:04:53Z","timestamp":1772190293374,"version":"3.50.1"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006400","name":"Alnylam Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006400","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,27]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Primary hyperoxaluria type 1 (PH1) is a rare genetic disorder of hepatic oxalate overproduction leading to kidney failure and systemic oxalosis. Lumasiran is an RNA interference therapeutic approved for lowering urinary oxalate (UOx) and plasma oxalate (POx) in PH1. This Phase 2 open-label extension (OLE) study evaluated the safety and efficacy of long-term lumasiran treatment (up to 54 months) in patients with PH1 who had completed the Phase 1\/2 parent study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The Phase 2 OLE (NCT03350451) included patients with PH1 6 to 64 years of age, 24-hour UOx excretion &amp;gt;0.7\u00a0mmol\/1.73 m2\/day, and estimated glomerular filtration rate (eGFR &amp;gt;45\u00a0ml\/min\/1.73 m2) who enrolled within 12 months of parent study completion. Patients initiated subcutaneous lumasiran at parent study dosage. Endpoints included adverse event (AE) incidence (primary) and change over time in efficacy measures, including 24-hour UOx and eGFR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>All 20 patients (median age 11.5 years; 65% female) who completed the parent study entered and completed the Phase 2 OLE. Of 21 treatment-related AEs over 427 doses, 13 were transient injection site reactions (ISRs), affecting 8\/20 patients (40%); all ISRs were mild in severity. After Month (M) 18 through M51 (last dosing), no ISRs were reported. No treatment-related severe or serious AEs were reported. Lumasiran treatment led to a substantial mean reduction in 24-hour UOx from baseline to M54 of \u22121.5\u00a0mmol\/24\u00a0h\/1.73 m2. At visits M42 through M54, 24-hour UOx was \u22641.5\u00a0\u00d7\u00a0ULN in 89%\u201394% of patients at each visit. The mean annual change in eGFR was \u22120.4\u00a0ml\/min\/1.73 m2\/year overall; eGFR was also stable in those patients with baseline eGFR &amp;lt;90\u00a0ml\/min\/1.73 m2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These data represent the longest published follow-up of lumasiran-treated patients with PH1 (ages 6\u201343 years) to date. Long-term lumasiran treatment for PH1 had acceptable safety and led to sustained and substantial reduction of UOx with preservation of kidney function.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ndt\/gfaf188","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T12:03:20Z","timestamp":1758283400000},"page":"575-583","source":"Crossref","is-referenced-by-count":1,"title":["Long-term lumasiran therapy final results from a Phase\u00a02 open-label extension study in primary hyperoxaluria"],"prefix":"10.1093","volume":"41","author":[{"given":"Yaacov","family":"Frishberg","sequence":"first","affiliation":[{"name":"Division of Pediatric Nephrology, Shaare Zedek Medical Center , Jerusalem , Israel, Faculty of Medicine, Hebrew University, Jerusalem,","place":["Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaap W","family":"Groothoff","sequence":"additional","affiliation":[{"name":"Emma Children\u2019s Hospital, Amsterdam UMC, University of Amsterdam Department of Pediatric Nephrology, , Amsterdam ,","place":["Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sally-Anne","family":"Hulton","sequence":"additional","affiliation":[{"name":"Birmingham Women\u2019s & Children\u2019s NHS Foundation Trust Department of Nephrology, , Birmingham ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerome","family":"Harambat","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire de Bordeaux Department of Pediatric Nephrology, , Bordeaux,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Hogan","sequence":"additional","affiliation":[{"name":"H\u00f4pital Robert Debr\u00e9 Department of Pediatric Nephrology, , APHP, ERKnet, Paris ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Laure","family":"Sellier-Leclerc","sequence":"additional","affiliation":[{"name":"H\u00f4pital Femme M\u00e8re Enfant en Centre d\u2019Investigation Clinique INSERM , Hospices Civils de Lyon, ERKnet, Bron ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wesley","family":"Hayes","sequence":"additional","affiliation":[{"name":"Great Ormond Street Hospital for Children NHS Pediatric Nephrology Department, , London ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin J","family":"Coenen","sequence":"additional","affiliation":[{"name":"Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn , Bonn ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Willey","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals , Cambridge, MA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John M","family":"Gansner","sequence":"additional","affiliation":[{"name":"Alnylam Pharmaceuticals , Cambridge, MA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniella","family":"Magen","sequence":"additional","affiliation":[{"name":"Pediatric Nephrology Institute, Rambam Health Care Campus , Haifa ,","place":["Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,9,22]]},"reference":[{"key":"2026022705020970800_bib1","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/s41581-022-00661-1","article-title":"Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and OxalEurope","volume":"19","author":"Groothoff","year":"2023","journal-title":"Nat Rev Nephrol"},{"key":"2026022705020970800_bib2","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1007\/s40265-022-01735-x","article-title":"Improving treatment options for primary hyperoxaluria","volume":"82","author":"Hoppe","year":"2022","journal-title":"Drugs"},{"key":"2026022705020970800_bib3","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1056\/NEJMra1301564","article-title":"Primary hyperoxaluria","volume":"369","author":"Cochat","year":"2013","journal-title":"N Engl J Med"},{"key":"2026022705020970800_bib4","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/21678707.2021.2003779","article-title":"Lumasiran: expanding the treatment options for patients with primary hyperoxaluria type 1","volume":"9","author":"Hulton","year":"2021","journal-title":"Expert Opin Orphan Drugs"},{"key":"2026022705020970800_bib5","article-title":"Primary hyperoxaluria type 1","author":"Milliner","year":"1993","journal-title":"Gene Rev"},{"key":"2026022705020970800_bib6","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1093\/ndt\/gfs078","article-title":"Primary hyperoxaluria type 1: indications for screening and guidance for diagnosis and treatment","volume":"27","author":"Cochat","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"2026022705020970800_bib7","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1007\/s00467-021-05002-1","article-title":"Long-term complications of systemic oxalosis in children-a retrospective single-center cohort study","volume":"36","author":"Ben-Shalom","year":"2021","journal-title":"Pediatr Nephrol"},{"key":"2026022705020970800_bib8","article-title":"Primary hyperoxaluria","author":"Danpure","year":"2019","journal-title":"The Online Metabolic and Molecular Bases of Inherited Disease"},{"key":"2026022705020970800_bib9","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s11832-008-0082-4","article-title":"Skeletal features of primary hyperoxaluria type 1, revisited","volume":"2","author":"El Hage","year":"2008","journal-title":"J Children's Orthopaed"},{"key":"2026022705020970800_bib10","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/ki.2009.435","article-title":"Genotype-phenotype correlation in primary hyperoxaluria type 1: the p.Gly170Arg AGXT mutation is associated with a better outcome","volume":"77","author":"Harambat","year":"2010","journal-title":"Kidney Int"},{"key":"2026022705020970800_bib11","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1253\/circj.CJ-10-0107","article-title":"Cardiac abnormalities in primary hyperoxaluria","volume":"74","author":"Mookadam","year":"2010","journal-title":"Circ J"},{"key":"2026022705020970800_bib12","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.nephro.2016.08.002","article-title":"Clinical spectrum of primary hyperoxaluria type 1: experience of a tertiary center","volume":"13","author":"Soliman","year":"2017","journal-title":"N\u00e9phrol Th\u00e9rapeut"},{"key":"2026022705020970800_bib13","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1097\/IAE.0b013e3182695a5b","article-title":"Crystalline retinopathy from primary hyperoxaluria","volume":"32","author":"Yuan","year":"2012","journal-title":"Retina"},{"key":"2026022705020970800_bib14","doi-asserted-by":"publisher","first-page":"468","DOI":"10.2215\/CJN.06820613","article-title":"Vitamin B6 in primary hyperoxaluria I: first prospective trial after 40 years of practice","volume":"9","author":"Hoyer-Kuhn","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026022705020970800_bib15","author":"Oxlumo. Package insert. Alnylam Pharmaceuticals","year":"2022"},{"key":"2026022705020970800_bib16","author":"Oxlumo. Summary of product characteristics. Alnylam Netherlands","year":"2022"},{"key":"2026022705020970800_bib17","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1056\/NEJMoa2021712","article-title":"Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1","volume":"384","author":"Garrelfs","year":"2021","journal-title":"N Engl J Med"},{"key":"2026022705020970800_bib18","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s00467-022-05684-1","article-title":"Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 12-month analysis of the phase 3 ILLUMINATE-B trial","volume":"38","author":"Hayes","year":"2023","journal-title":"Pediatr Nephrol"},{"key":"2026022705020970800_bib19","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.gim.2021.10.024","article-title":"Phase 3 trial of lumasiran for primary hyperoxaluria type 1: a new RNAi therapeutic in infants and young children","volume":"24","author":"Sas","year":"2022","journal-title":"Genet Med"},{"key":"2026022705020970800_bib20","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1053\/j.ajkd.2022.05.012","article-title":"Lumasiran for advanced primary hyperoxaluria type 1: phase 3 ILLUMINATE-C trial","volume":"81","author":"Michael","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"2026022705020970800_bib21","author":"Magen"},{"key":"2026022705020970800_bib22","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.2215\/CJN.14730920","article-title":"Phase 1\/2 study of lumasiran for treatment of primary hyperoxaluria type 1: a placebo-controlled randomized clinical trial","volume":"16","author":"Frishberg","year":"2021","journal-title":"CJASN"},{"key":"2026022705020970800_bib23","author":"World Medical Association","year":"2013"},{"key":"2026022705020970800_bib24","author":"International Council for Harmonisation Working Group","year":"1996"},{"key":"2026022705020970800_bib25","doi-asserted-by":"publisher","first-page":"481","DOI":"10.4155\/bio-2022-0227","article-title":"Quantification of oxalate by novel LC-MS\/MS: assay development, validation and application in lumasiran clinical trials","volume":"15","author":"Clausen","year":"2023","journal-title":"Bioanalysis"},{"key":"2026022705020970800_bib26","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1681\/ASN.2008030287","article-title":"New equations to estimate GFR in children with CKD","volume":"20","author":"Schwartz","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2026022705020970800_bib27","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2026022705020970800_bib28","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ekir.2023.10.004","article-title":"Multicenter long-term real world data on treatment with lumasiran in patients with primary hyperoxaluria type 1","volume":"9","author":"Martin-Higueras","year":"2024","journal-title":"Kidney Int Rep"},{"key":"2026022705020970800_bib29","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1016\/j.ekir.2024.04.048","article-title":"Efficacy and safety of lumasiran in patients with primary hyperoxaluria type 1: results from a phase III clinical trial","volume":"9","author":"Saland","year":"2024","journal-title":"Kidney Int Rep"},{"key":"2026022705020970800_bib30","author":"Michael"},{"key":"2026022705020970800_bib31","author":"Gansner"},{"key":"2026022705020970800_bib32","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/ki.2014.222","article-title":"Data from a large European study indicate that the outcome of primary hyperoxaluria type 1 correlates with the AGXT mutation type","volume":"86","author":"Mandrile","year":"2014","journal-title":"Kidney Int"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfaf188\/64345869\/gfaf188.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/3\/575\/64345869\/gfaf188.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/3\/575\/64345869\/gfaf188.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T10:02:14Z","timestamp":1772186534000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/41\/3\/575\/8261537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,22]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,9,22]]},"published-print":{"date-parts":[[2026,2,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfaf188","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2025,9,22]]}}}